Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that 1′S-1′-acetoxychavicol acetate from Alpinia galanga inhibits Nox isozymes and suppresses testosterone-induced hair loss in a mouse model of androgenetic alopecia.

This study tested a novel cryo-carboxy dispensing device for treating androgenetic alopecia in six volunteers and found an unexpectedly rapid and positive response, with significant hair regrowth observed by day 90, prompting early conclusion of the trial.

The researchers reported that nano-cerium oxide improved androgenetic alopecia in mice by increasing the ratio of terminal to vellus hairs, elevating IGF-1 expression, and reducing TGF-β and DHT levels in the skin, suggesting potential for drug development.

This study found that the combination of finasteride and black soybean extract showed synergistic protective effects against DHT-induced damage in hair follicle cells, suggesting potential benefits for treating androgenetic alopecia.

In this case series, researchers reported an unexpectedly rapid and positive response to a topical, hydrogel-based botanical treatment for androgenetic alopecia in both male and female volunteers, achieving significant improvement in hair loss within 90 days instead of the planned 270 days.

This research found that exosome-derived long non-coding RNA AC010789.1, modified by FTO and hnRNPA2B1, enhanced human hair follicle stem cell proliferation against androgenic alopecia through the activation of S100A8/Wnt/β-catenin signaling pathways.

The research aims to better understand hair follicle regulation and find new treatments for hair loss.

This article critiques a study on finasteride use among individuals with benign prostatic hyperplasia and androgenetic alopecia, highlighting the flawed methodology and potential confounding effects of hair loss on mental health, which confuses interpretation of psychiatric risk.

This study found that individuals with early-onset androgenetic alopecia showed significant differences in metabolic parameters compared to those with normal-onset alopecia, suggesting a potential link between androgenetic alopecia and metabolic syndrome. However, the nature of this relationship remains uncertain.

In this study, PRP combined with minoxidil was found to be more effective in improving hair counts in androgenetic alopecia patients compared to minoxidil alone or with dermaroller, showing significant improvements at both 3 and 5 months.

This review discusses current and emerging therapies for androgenetic alopecia, emphasizing regenerative treatments and nanotechnology advancements, but it reports no new clinical results.

In this study, low-dose oral minoxidil was found to be an effective and safe treatment for androgenetic alopecia, showing comparable outcomes in patients with AGA alone and those with AGA unmasked by telogen effluvium.

In this cross-sectional study, researchers observed that individuals with early-onset androgenetic alopecia showed significant differences in hair growth parameters and metabolic factors compared to those with normal-onset AGA, suggesting a potential association with metabolic syndrome, though more research is needed to clarify this relationship.

This study found that the topical Shen Bai hair growing decoction may improve androgenetic alopecia in mice by suppressing TNF-α and IL-6 levels, enhancing follicle density, and reducing apoptosis.

In this study, researchers found that Derinat, a TRPCs inhibitor, reduced oxidative stress and prolonged the anagen phase of hair growth in mice, supporting its potential as a therapy for androgenetic alopecia by improving clinical outcomes and enhancing quality of life for those affected.

This review of SVF treatment for androgenetic alopecia found a significant increase in hair density across studies with no serious adverse events, but calls for standardized protocols and further research.

This study investigated AGA professionals' perspectives and found that 42% were misled by commercial influences, underestimated these biases' extent, and faced ethical challenges in treatment due to societal pressures and misinformation, highlighting a need for evidence-based guidance and research scrutiny tools.

This study observed that both finasteride and dutasteride significantly decreased dihydrotestosterone concentrations in hair, with dutasteride showing the greatest reduction.

In this animal study, researchers observed that ginsenoside CK significantly reduced hair loss, improved sexual organ health, and encouraged hair growth in mice with androgenetic alopecia by modulating key signaling pathways and normalizing hormone metabolism, highlighting its potential as a therapeutic agent.

The researchers reported that an oral supplement containing hydrolysed fish-origin collagen, taurine, cysteine, methionine, iron, and selenium significantly improved the effectiveness of anti-hair loss treatments in people with androgenic alopecia or chronic telogen effluvium after 12 weeks, compared to drug treatments alone.

This paper describes pattern or androgenetic alopecia as a genetically defined condition caused by an overreaction to androgens, affecting up to 50% of post-pubertal males and females, characterized by progressive hair loss patterns that differ between genders.

This study found that a combination of topical 5% minoxidil and 0.25% finasteride was more effective at improving hair density and satisfaction in men with androgenetic alopecia than either treatment alone over 24 weeks.

This article discusses various treatments for androgenetic alopecia and reports no new clinical results, noting the condition's aesthetic and psychological impact.

This article reviews the use of green tea for hair loss prevention and regrowth, highlighting its potential effects on dermal papillae, but reports no new clinical results.

Combining PRP with other treatments can improve hair loss outcomes.

This study found that androgenic alopecia is common in polycystic ovary syndrome, correlates with other hyperandrogenism signs, but not with increased biochemical or metabolic risk compared to PCOS alone.

This study found that before finasteride was available, fewer than 20% of men were satisfied with over-the-counter hair loss treatments, and more than half wanted to consult a medical professional.

This study found that 1mg/d oral finasteride was effective and safe for treating androgenetic alopecia in men, with better results observed in patients aged 26 or younger.

This study reported that multiple factors including genetics and psychological influences are related to androgenetic alopecia, and finasteride showed a 77.8% response rate after three months of treatment.

This study explored chitosan-based dissolving microneedle arrays loaded with Agave tequilana root extract, finding that extract concentration influenced microneedle geometry and bioactivity, maintaining antioxidant and enzyme inhibitory effects while reducing collagenase inhibition, particularly in the 0.25% formulation.